A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

Investigational New Drugs

Volumn 29, Issue 2, 2011, Pages 366-373

  Kim, Chul ^a   Lee, Jae Lyun ^a   Ryu, Min Hee ^a   Chang, Heung Moon ^a   Kim, Tae Won ^a   Lim, Ho Young ^b   Kang, Hye Jin ^c   Park, Young Suk ^b   Ryoo, Baek Yeol ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Capecitabine; Cetuximab; Gastric cancer; Oxaliplatin; Targeted therapy

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ABDOMINAL METASTASIS; ABDOMINAL PAIN; ACNE; ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ASTHENIA; BONE METASTASIS; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM METASTASIS; ESCHERICHIA COLI SEPSIS; FEMALE; GRAM NEGATIVE SEPSIS; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; LEUKOCYTE COUNT; LIVER METASTASIS; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; MALE; METASTASIS; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NECK METASTASIS; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OVARY METASTASIS; OVERALL SURVIVAL; PANCREAS METASTASIS; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BLEEDING; VOMITING; ARTICLE; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RECURRENT DISEASE; STOMACH TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 79957539777     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-009-9363-0     Document Type: Review

References (31)

1. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578 (Pubitemid 43209104)
2. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654 (Pubitemid 46211507)
3. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810 (Pubitemid 46211358)
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345 (Pubitemid 38944402)
5. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
6. De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ et al (1998) Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 28:971-979 (Pubitemid 28450257)
7. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P et al (2006) Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450-456 (Pubitemid 43329582)
8. Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P et al (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10:234-241 (Pubitemid 40486955)
9. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168 (Pubitemid 27112884)
10. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS et al (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100:298-304
11. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N et al (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578-5587
12. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH et al (2004) A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15:1344-1347 (Pubitemid 39295021)
13. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048 (Pubitemid 350106711)
14. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666-673
15. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST et al (2002) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13:1893-1898 (Pubitemid 36049952)
16. Kopp R, Ruge M, Rothbauer E, Cramer C, Kraemling HJ, Wiebeck B et al (2002) Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 22:1161-1167 (Pubitemid 34836167)
17. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M et al (2008) Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15:69-79
18. Lordick FLS, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E et al (2007) Cetuximab plus weekly oxaliplatin/ 5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. J Clin Oncol 4526
19. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281 (Pubitemid 28342121)
20. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, RauschM(1993)Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41 (Pubitemid 23182046)
21. Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS et al (2008) Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol 61:623-629
22. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
23. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C et al (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510-517 (Pubitemid 46359631)
24. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
25. Raymond E, Faivre S, Armand JP (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60(Suppl 1):15-23 discussion 41-2
26. Sakamoto J, Chin K, Kondo K, Kojima H, Terashima M, Yamamura Y et al (2006) Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 17:231-236
27. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208 (Pubitemid 41079832)
28. Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M et al (1998) Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Res 18:2727-2732 (Pubitemid 28386573)
29. Tabernero J, Macarulla T, Ramos FJ, Baselga J (2005) Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16:1740-1748 (Pubitemid 41637612)
30. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T et al (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 75:1418-1425
31. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997 (Pubitemid 46631401)